Unlock the Editor’s Digest at no cost
Roula Khalaf, Editor of the FT, selects her favorite tales on this weekly publication.
It wasn’t way back that CVS Well being appeared poised to grow to be a US healthcare heavyweight. The nation’s largest drugstore operator owned Caremark, the pharmacy advantages supervisor and a dependable revenue centre.
In 2017, it pushed into insurance coverage, shopping for Aetna for $78bn, together with debt. It then spent almost $20bn on care suppliers Signify Well being and Oak Avenue Well being.
The thought was that CVS shops would grow to be a one-stop store, and profit from synergies by bringing so many components of the healthcare chain below one roof.
It hasn’t labored out that means. CVS reduce its full-year earnings outlook in August for the third time this yr. Its market worth of $80bn is lower than what it has spent on acquisitions.
Web debt has ballooned to $50bn — thrice this yr’s anticipated ebitda. It has attracted the eye of hedge fund Glenview Capital Administration.
CVS’s board is reportedly reviewing its choices. However a break-up would doubtless generate loads of banker charges however little else.
Take the healthcare advantages enterprise. A push to enrol extra seniors to its Aetna Medicare Benefit plans backfired.
New prospects introduced a surge in medical claims — simply as the federal government began to clamp down on reimbursement charges.
The medical profit ratio — what quantity of premiums collected is paid out to suppliers — was 89.6 per cent within the second quarter, versus 86.2 per cent a yr earlier than.
In regular occasions, a standalone insurance coverage enterprise might command a better valuation. Market chief UnitedHealth trades on shut to twenty occasions ahead earnings in comparison with CVS on 9 occasions.
However Aetna’s troubles have hit CVS’s shares. Given uncertainty over Medicare fee charges, a premium valuation appears unlikely.
It’s a comparable story in well being providers. This unit, which incorporates Caremark, is CVS’s largest, accounting for about half of group income and working revenue.
However US regulators are suing it — and two different PBMs — for allegedly inflating insulin drug costs. CVS has mentioned the accusations have been “merely incorrect”. However regulatory overhang might dampen enthusiasm for a PBM-focused inventory.
Then there may be the legacy drugstore enterprise. This sector is in secular decline. Amazon and rival retailers like Walmart have chipped away at gross sales of front-of-store choices, like sweet and toothpaste. Falling reimbursement charges and cheaper generics are squeezing prescription drug margins.
Nonetheless, CVS’s retail enterprise has held up higher than Ceremony Support, now bust, and Walgreens Boots Alliance, aggressively shrinking. That’s partly because of Caremark, which has helped to funnel sufferers to its pharmacies. A cut up would finish that relationship. Not all illnesses require radical surgical procedure.
